Research programme: fluorinated CNS and cancer therapeutics - Trillium Therapeutics

Drug Profile

Research programme: fluorinated CNS and cancer therapeutics - Trillium Therapeutics

Alternative Names: FV-082; FV-137; FV-162; FV-214; FV-222; FV-225; FV-281; TTI 281

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Fluorinov Pharma
  • Developer Trillium Therapeutics Inc
  • Class Small molecules
  • Mechanism of Action Apoprotein inhibitors; Apoptosis inhibitors; Bromodomain and extraterminal domain protein inhibitors; Epidermal growth factor receptor antagonists; Nav1.7-voltage-gated-sodium-channel-modulators; Nav1.8 voltage-gated sodium channel modulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cancer; Cancer pain; Epilepsy; Glioblastoma; Lung cancer; Multiple myeloma; Pancreatic cancer
  • No development reported CNS disorders; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 03 Dec 2016 Pharmacokinetics, pharmacodynamics and safety data from a preclinical study in Multiple myeloma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 03 Dec 2016 Pharmacodynamics data from a preclinical trials in Cancer presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 03 Nov 2016 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top